TEM
NASDAQTempus AI Inc.
News25/Ratings12
News · 26 weeks122-79%
2025-12-282026-06-21
Mix7390d
- Other34(47%)
- Insider24(33%)
- SEC Filings9(12%)
- Analyst3(4%)
- Earnings2(3%)
- Leadership1(1%)
Latest news
25 items- PR16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart GapIssued on behalf of Ventripoint Diagnostics Ltd.As the number of people living with congenital heart disease climbs and most patients in poorer regions go without timely care, a Toronto-based AI imaging company is joining a new global alliance built to close that gap.TORONTO, ON, June 16, 2026 /CNW/ -- Equity Insider News Commentary — Congenital heart disease is the most common birth defect in the world, and the population living with it is growing, not shrinking. According to the World Heart Federation's World Heart Report 2026, congenital heart disease now affects roughly 2% of live births globally, and the number of people living with the condition has climbed to an estimated 16 million w
- PRTempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart RhythmTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled "Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Flutter," was recently published in Heart Rhythm. AF is the most prevalent cardiac arrhythmia and is associated with an increased risk of stroke, heart failure and death. Because AF is frequently asymptomatic and paroxysmal, it
- PRGenetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome TestingResearch highlights how ExomeReveal RNA analysis resolves ambiguity around uncertain variants to enable more genetic disease diagnoses Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM), announced peer-reviewed research demonstrating the potential for variant-specific RNA testing to provide greater clarity for patients who receive a variant of uncertain significance (VUS) result from exome testing. The study, published in Genetics in Medicine Open, showcases how targeted RNA analysis using Ambry's ExomeReveal workflow; an innovative multiomics exome sequencing approach can help resolve uncertain findings and improve diagnost
- PRTempus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00 p.m. ET on Monday, June 8. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision
- INSIDERDirector Epstein David R sold $12,350 worth of shares (250 units at $49.40) as part of a pre-agreed trading plan, decreasing direct ownership by 0.79% to 31,464 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- PRTempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding MembersTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of a digital pathology IMS Open-Source Consortium ("IMS Consortium"). Designed to accelerate the democratization and standardization of digital pathology, the consortium aims to bring together leading academic medical centers and industry partners to develop a best-in-class open-source digital pathology platform and viewer. YNHH and MSK are founding academic members of the consortium. As pioneering institutions, they will contribute to defining the vision, governance, and stra
- ANALYSTWolfe Research resumed coverage on Tempus AIWolfe Research resumed coverage of Tempus AI with a rating of Peer Perform
- PRTempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xHTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a whole-genome sequencing (WGS) approach for the detection of actionable oncologic targets in peripheral blood and bone marrow samples from patients with hematologic malignancies. Tempus first announced the xH assay for research use only in January 2025. The test was developed for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and overlap syndromes (MDS/MPN). It is optimized for myeloid neoplasms and is designed to su
- PRTempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug DevelopmentTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus' multimodal data, AI tooling and computational infrastructure to deliver actionable insights at the pace required for drug development. The next-generation of the Lens platform is built on over a decade of longitudinal real-world data and years of expertise translating that data into actionable evidence for biopharma. Lens combines one of the world's largest real-world multimodal datasets, high-
- PRTempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research CommunityInaugural program provides unprecedented access to Tempus' library of de-identified multimodal data and models, scalable compute infrastructure and direct funding to catalyze clinical and technical breakthroughs Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the PRECISION Challenge, a national initiative engineered to accelerate the next generation of oncology breakthroughs leveraging its foundational model. The PRECISION Challenge aims to unlock breakthroughs in oncology at scale by providing access to data, funding, and expertise to multidisciplinary teams around the world who seek to make bold a
- PRTempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive ResultsTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically significant insights that close the gap between the time of order and delivery of insights. Representing a significant paradigm shift in precision oncology workflows, Tempus Preview offers preliminary results in the critical window between when a diagnostic test is ordered and when final sequencing results are delivered by surfacing key mutation predictions within approximately 24 hours of tissue receipt. The initial days following an advanced cancer diagnosis are critical for strategic t
- INSIDERCEO and Chairman Lefkofsky Eric P sold $7,763,312 worth of shares (166,250 units at $46.70) as part of a pre-agreed trading plan (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- PRTempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in OncologyTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus has been building novel biological foundation models and agentic workflows by leveraging its more than 500 petabytes of rich, molecularly grounded data—more than 45 million total de-identified patient journeys, 1.5 million with sequenced data, and over 400,000 records in cancer with full genomic, transcriptomic, imaging, and clinical data. These efforts transform this data into unified patient representations, unlock
- PRTempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor PortfolioTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling. Tempus xT CDx is a 648-gene tissue-based assay intended for molecular profiling of all solid tumor malignancies. It also serves as a companion diagnostic to identify colorectal cancer patients who may benefit from targeted therapies, specifically
- PRTempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across OncologyExpanded platform delivers patient insights across six new clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a significant expansion of new indications to its AI-enabled Next platform ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Next establishes a new category of "real-time clinical intelligence" — a departure from legacy retrospective analyses and generic EHR alerts — designed to facilitate the delivery of precision medicine. To demonstrate the real-world impact of these expanded capabilities, Te
- SECSEC Form 144 filed by Tempus AI Inc.144 - Tempus AI, Inc. (0001717115) (Subject)
- PRTempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical WorkflowsTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a major technological upgrade to Tempus Hub, its AI-enabled smart physician platform. Tempus is making available its advanced, next-generation generative AI clinical co-pilot directly in Hub to power an agent-first experience for healthcare providers, allowing them to integrate the benefits of large language models and generative AI capabilities with their diagnostic results to better treat cancer patients This upgrade connects Tempus' most advanced agentic AI capabilities directly with real-time patient data inside the Hub environment, scaling how providers utilize
- INSIDERDirector Belcher Eric D was granted 5,913 units of Class A Comnmon Stock, increasing direct ownership by 38% to 21,424 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERDirector Epstein David R was granted 5,913 units of Class A Comnmon Stock, increasing direct ownership by 23% to 31,714 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERDirector Gottlieb Scott was granted 5,913 units of Class A Comnmon Stock, increasing direct ownership by 17% to 40,749 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERDirector Frederick Wayne A.I. was granted 5,913 shares, increasing direct ownership by 24% to 30,749 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERDirector Leonsis Theodore was granted 5,913 units of Class A Comnmon Stock, increasing direct ownership by 38% to 21,424 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERDirector West Nadja was granted 5,913 shares, increasing direct ownership by 18% to 37,981 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERDirector Barris Peter J was granted 5,913 shares, increasing direct ownership by 5% to 121,424 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
- INSIDERDirector Doudna Jennifer A was granted 5,913 units of Class A Comnmon Stock, increasing direct ownership by 26% to 28,615 units (SEC Form 4)4 - Tempus AI, Inc. (0001717115) (Issuer)
TEM FAQ
6 questionsWhere does TEM stock trade?
Tempus AI Inc. (TEM) is listed on NASDAQ.What sector and industry is TEM in?
Tempus AI Inc. operates in the Technology sector, Computer Software: Programming Data Processing industry.When did Tempus AI Inc. go public?
Tempus AI Inc. (TEM) completed its IPO in 2024.What are analysts saying about TEM?
Tempus AI Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-06-02. Recent price targets cluster around $3500.00.What companies are similar to TEM?
Notable peers in the same industry include GOOGL (Alphabet Inc.), GOOG (Alphabet Inc.), META (Meta Platforms Inc.), APP (Applovin Corporation), NBIS (Nebius Group N.V.). Compare TEM side-by-side with any of them on Quantisnow.How can I track TEM on Quantisnow?
Quantisnow aggregates Tempus AI Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TEM to receive live email and push alerts on every new disclosure.